Natural Capsules Ltd
Incorporated in 1993, Natural Capsules manufactures Capsules and Steroidal APIs and their Intermediates and Derivatives[1]
- Market Cap ₹ 299 Cr.
- Current Price ₹ 320
- High / Low ₹ 421 / 255
- Stock P/E 53.8
- Book Value ₹ 219
- Dividend Yield 0.30 %
- ROCE 4.52 %
- ROE 3.15 %
- Face Value ₹ 10.0
Pros
Cons
- Company has a low return on equity of 10.8% over last 3 years.
- Company might be capitalizing the interest cost
- Debtor days have increased from 104 to 128 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|
55 | 60 | 62 | 80 | 135 | 170 | 155 | |
49 | 55 | 56 | 68 | 110 | 135 | 136 | |
Operating Profit | 6 | 5 | 5 | 11 | 26 | 35 | 20 |
OPM % | 10% | 8% | 9% | 14% | 19% | 21% | 13% |
1 | 1 | 1 | 3 | 1 | 1 | 2 | |
Interest | 0 | 1 | 1 | 1 | 2 | 4 | 5 |
Depreciation | 4 | 3 | 4 | 4 | 5 | 7 | 9 |
Profit before tax | 2 | 2 | 1 | 9 | 19 | 25 | 8 |
Tax % | 34% | 7% | 38% | 24% | 28% | 26% | 31% |
1 | 2 | 1 | 7 | 14 | 18 | 6 | |
EPS in Rs | 1.19 | 2.06 | 0.92 | 7.43 | 14.96 | 20.14 | 5.95 |
Dividend Payout % | 56% | 32% | 43% | 9% | 5% | 5% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 21% |
3 Years: | 25% |
TTM: | -9% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 21% |
3 Years: | 2% |
TTM: | -70% |
Stock Price CAGR | |
---|---|
10 Years: | 26% |
5 Years: | 44% |
3 Years: | 37% |
1 Year: | -13% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 9% |
3 Years: | 11% |
Last Year: | 3% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|
Equity Capital | 6 | 6 | 6 | 6 | 7 | 9 | 9 |
Reserves | 48 | 49 | 49 | 56 | 76 | 114 | 194 |
0 | 5 | 6 | 10 | 53 | 97 | 109 | |
19 | 14 | 14 | 26 | 29 | 70 | 64 | |
Total Liabilities | 73 | 75 | 76 | 99 | 165 | 290 | 377 |
22 | 24 | 24 | 38 | 66 | 97 | 103 | |
CWIP | 1 | 2 | 2 | 7 | 20 | 88 | 144 |
Investments | 5 | 5 | 6 | 0 | 0 | 0 | 3 |
45 | 43 | 45 | 54 | 79 | 105 | 127 | |
Total Assets | 73 | 75 | 76 | 99 | 165 | 290 | 377 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|
5 | 2 | 7 | 6 | -1 | 17 | -8 | |
-1 | -7 | -6 | -9 | -46 | -105 | -73 | |
-4 | 4 | -1 | 3 | 48 | 87 | 82 | |
Net Cash Flow | 0 | -1 | 0 | -0 | 1 | 0 | 1 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|
Debtor Days | 208 | 197 | 180 | 123 | 71 | 112 | 128 |
Inventory Days | 149 | 87 | 89 | 82 | 34 | 45 | 88 |
Days Payable | 185 | 114 | 91 | 157 | 98 | 127 | 141 |
Cash Conversion Cycle | 172 | 170 | 179 | 48 | 7 | 30 | 75 |
Working Capital Days | 186 | 176 | 158 | 120 | 121 | 117 | 176 |
ROCE % | 5% | 4% | 11% | 21% | 15% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
6m - Copies of Newspaper publication in Sanjevani and Business Line wrt to 31st AGM of the Company.
- Intimation Of Record Date For AGM 1d
-
Notice Of Annual General Meeting
1d - Notice of 31st AGM scheduled to be on Friday, July 26, 2024 at 11.00 AM through VC or OAVM. The details along with Notice are …
- Notice Of 31St AGM 1d
- Reg. 34 (1) Annual Report. 1d
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Concalls
-
May 2024Transcript PPT
-
Feb 2024TranscriptNotesPPT
-
Nov 2023TranscriptPPT
-
Nov 2023Transcript PPT
-
Aug 2023TranscriptNotesPPT
-
Jun 2023Transcript PPT
-
Feb 2023TranscriptNotesPPT
-
Oct 2022TranscriptNotesPPT
-
Aug 2022TranscriptNotesPPT
-
May 2022TranscriptNotesPPT
-
Feb 2022TranscriptNotesPPT
-
Nov 2021TranscriptNotesPPT
Business Overview:[1][2][3]
NCL is a WHO-GMP certified and ISO 9001, ISO 140001 compliance manufacturer of printed and unprinted hard two-piece Gelatin and Cellulose (HPMC : non-animal alternative) capsules for pharmaceutical and dietary supplement industries in various sizes of 00, 0el, 0, 1, 2, 3 & 4. Apart from this, NCL has forayed into API manufacturing with complex high-end patented technology developed in-house, under its subsidiary company Natural Biogenex Private Limited.